PTC Therapeutics Q3 2026 Results: Net Loss of $51.7M
For the nine months ended September 30, 2026, PTC Therapeutics reported total revenues of $990.9 million and net income of $29.0 million, a significant decrease from the $817.6 million net income in the prior year period which was bolstered by high collaboration revenue. The company's balance sheet remains strong with $2.1 billion in cash, cash equivalents, and marketable securities, though it maintains a total stockholders' deficit of $191.2 million.
- Key figure
- Net loss $51.7M